Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic therapy for gynecologic cancer

J J Kavanagh1, A P Kudelka

  • 1University of Texas MD Anderson Cancer Center, Houston.

Current Opinion in Oncology
|September 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physiological tremor is suppressed and force steadiness is enhanced with increased availability of serotonin regardless of muscle fatigue.

Journal of neurophysiology·2021
Same author

Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.

Gynecologic oncology·2017
Same author

Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy.

Gynecologic oncology·2011
Same author

What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?

Journal of chemotherapy (Florence, Italy)·2009
Same author

Ovarian endometriosis associated with carcinoma and sarcoma: case report.

European journal of gynaecological oncology·2008
Same author

Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin.

Investigational new drugs·2008
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Recent gynecologic cancer studies highlight novel chemotherapeutics like irinotecan and taxanes for ovarian cancer, alongside biologic agents for ascites palliation. Advances are also noted in cervical, trophoblastic, endometrial, and uterine sarcoma treatments.

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Chemotherapy

Background:

  • Long-term ovarian cancer follow-up confirms poor survival rates.
  • Novel chemotherapeutic agents are emerging for gynecologic malignancies.
  • Biologic agents and new treatment strategies are under investigation.

Purpose of the Study:

  • To review recent advancements in the treatment of various gynecologic cancers.
  • To highlight novel therapeutic agents and approaches in gynecologic oncology.
  • To discuss progress in managing ovarian, cervical, trophoblastic, endometrial, and uterine sarcoma diseases.

Main Methods:

  • Review of recent studies presented in gynecologic oncology.
  • Discussion of novel chemotherapeutics including topoisomerase I inhibitors and taxanes.

Related Experiment Videos

  • Exploration of biologic agents, retinoids, interferons, and scoring criteria.

    • Main Results:

    • Second-generation topoisomerase I inhibitors (irinotecan, topotecan) and taxanes show activity.
    • Monoclonal antibodies are being developed for ascites palliation in ovarian cancer.
    • Retinoids and interferons offer new avenues for cervical cancer treatment.
    • Improved primary treatment for trophoblastic disease using WHO criteria.
    • Advances noted in salvage therapy and treatment for advanced endometrial cancer and uterine sarcomas.

    Conclusions:

    • Significant progress is being made in the treatment of various gynecologic cancers.
    • Novel therapeutic agents and strategies are expanding treatment options.
    • Ongoing research promises improved outcomes for patients with gynecologic malignancies.